COMMUNIQUÉS West-GlobeNewswire

Synthorx Reports Second Quarter Financial Results
01/08/2019
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results [...]
Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
01/08/2019
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic [...]
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
01/08/2019
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the [...]
Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update
01/08/2019
- Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing – – Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration – – Additional Phase 2 data in [...]
Fluidigm Announces Second Quarter 2019 Financial Results
01/08/2019
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass Cytometry Panel Kits [...]
Guardant Health to Report Second Quarter 2019 Financial Results on August 6, 2019
01/08/2019
REDWOOD CITY, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the second quarter 2019 after market close on Tuesday, August 6, 2019. [...]
Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data
01/08/2019
Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020 Results from Serlopitant Phase 3 Clinical Trials for the Treatment of Pruritus with Prurigo [...]
Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results
01/08/2019
BERKELEY, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and [...]
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019
01/08/2019
Reaffirms full year 2019 financial forecast and operational goals Provides Q3 2019 revenue forecast of $245M-$275M GAITHERSBURG, Md., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported [...]
SeaSpine Reports Second Quarter 2019 Financial Results
01/08/2019
Increases 2019 Financial Outlook CARLSBAD, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of [...]
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
01/08/2019
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated [...]
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
01/08/2019
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company ended the second quarter [...]
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
01/08/2019
PRINCETON, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten [...]
Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
01/08/2019
- Regulatory submission for LN-145 in advanced cervical cancer expected in the second half of 2020 - - Company to host conference call at 4:30 p.m. EDT today - SAN CARLOS, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- [...]
CareDx Reports Second Quarter 2019 Results
01/08/2019
AlloSure momentum drives 76% second quarter revenue growth BRISBANE, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development and [...]
Jonathan Day Named VP, Commercial Operations, Americas
01/08/2019
Seasoned Commercial Leader with Track Record in Life Sciences and Diagnostics SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Jonathan [...]
Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
01/08/2019
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in [...]
Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
01/08/2019
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet [...]
Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update
01/08/2019
Strong Crysvita® (burosumab) Launch Continues with Approximately 960 Patients on Reimbursed Commercial Therapy in the United States Ultragenyx Submits New Drug Application to FDA for UX007 (triheptanoin) for Treatment [...]

Pages